Canton Strategic Holdings (CNTN) Common Equity (2020 - 2026)
Canton Strategic Holdings (CNTN) reported Common Equity of $469.8 million for Q1 2026, up 57767.37% on a YoY basis from N/an in Q1 2025, and up 18.06% quarter-over-quarter from $397.9 million in Q4 2025.
Canton Strategic Holdings (CNTN) Common Equity (2020 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Common Equity for 7 years, with the latest figure at $469.8 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 57767.37% year-over-year to $469.8 million; the trailing twelve-month figure through Mar 2026 stood at $469.8 million (up 57767.37% YoY), and the FY2025 full-year result was $397.9 million, up 30330.8% from the prior year.
- Common Equity for Q1 2026 stood at $469.8 million, up from $397.9 million in the prior quarter.
- The five-year high for Common Equity was $469.8 million in Q1 2026, with the low at -$814671.0 in Q1 2025.
- Historically, Common Equity has averaged $55.3 million across 5 years, with a median of $6.2 million in 2025.
- Annual changes were most pronounced in 2025 — Common Equity plunged 111.56% — and 2026, when it jumped 57767.37%.
- Canton Strategic Holdings' Common Equity stood at $5.5 million in 2022, then soared by 64.72% to $9.1 million in 2023, then slumped by 85.68% to $1.3 million in 2024, then jumped by 30330.8% to $397.9 million in 2025, then rose by 18.06% to $469.8 million in 2026.
- The last three Common Equity figures came in at $469.8 million (Q1 2026), $397.9 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | 469.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 469.80 Mn |
| Dec 31, 2025 | 397.93 Mn |
| Sep 30, 2025 | 6.15 Mn |
| Jun 30, 2025 | 367,359.00 |
| Mar 31, 2025 | -814,671.00 |
| Dec 31, 2024 | 1.31 Mn |
| Sep 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 6.69 Mn |
| Mar 31, 2024 | 7.05 Mn |
| Dec 31, 2023 | 9.13 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 3.07 Mn |
| Mar 31, 2023 | 3.20 Mn |
| Dec 31, 2022 | 5.54 Mn |
| Sep 30, 2022 | 7.12 Mn |
| Jun 30, 2022 | 9.04 Mn |
| Mar 31, 2022 | 10.34 Mn |
| Dec 31, 2021 | -4.68 Mn |
| Sep 30, 2021 | -7.14 Mn |
| Jun 30, 2021 | -6.30 Mn |